Stockscreener 앱 받기
646.60
1.42%
9.04
시간 외 거래:
646.60
전일 마감가:
$637.56
열려 있는:
$640.19
하루 거래량:
416.01K
Relative Volume:
1.02
시가총액:
$39.57B
수익:
$3.05B
순이익/손실:
$1.28B
주가수익비율:
33.02
EPS:
19.58
순현금흐름:
$-614.78M
1주 성능:
-3.94%
1개월 성능:
+15.41%
6개월 성능:
-0.73%
1년 성능:
+21.76%
1일 변동 폭
$637.04
$651.00
1주일 범위
$631.47
$675.44
52주 변동 폭
$510.06
$696.21
알제넥스 NV ADR Stock (ARGX) Company Profile
ARGX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ARGX
Argen X Se Adr
|
646.60 | 39.02B | 3.05B | 1.28B | -614.78M | 19.58 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.92 | 99.42B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
561.55 | 58.99B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
432.52 | 56.35B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ONC
Beone Medicines Ltd Adr
|
307.51 | 34.25B | 3.81B | -644.79M | -669.77M | -6.24 |
알제넥스 NV ADR Stock (ARGX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-07-08 | 업그레이드 | Deutsche Bank | Hold → Buy |
| 2025-07-03 | 재개 | Morgan Stanley | Overweight |
| 2025-05-13 | 업그레이드 | Robert W. Baird | Neutral → Outperform |
| 2025-03-17 | 업그레이드 | Bernstein | Mkt Perform → Outperform |
| 2025-03-12 | 업그레이드 | Deutsche Bank | Sell → Hold |
| 2025-01-17 | 다운그레이드 | Deutsche Bank | Hold → Sell |
| 2024-11-12 | 업그레이드 | Wolfe Research | Peer Perform → Outperform |
| 2024-11-05 | 업그레이드 | Scotiabank | Sector Perform → Sector Outperform |
| 2024-11-01 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2024-11-01 | 업그레이드 | William Blair | Mkt Perform → Outperform |
| 2024-10-10 | 재개 | Raymond James | Strong Buy |
| 2024-10-04 | 다운그레이드 | Deutsche Bank | Buy → Hold |
| 2024-08-06 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2024-07-25 | 업그레이드 | Deutsche Bank | Hold → Buy |
| 2024-07-23 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2024-02-15 | 개시 | Wolfe Research | Peer Perform |
| 2023-12-20 | 다운그레이드 | Deutsche Bank | Buy → Hold |
| 2023-12-20 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2023-07-31 | 개시 | Scotiabank | Sector Perform |
| 2023-07-24 | 다운그레이드 | UBS | Buy → Neutral |
| 2023-07-17 | 재개 | Evercore ISI | Outperform |
| 2023-06-15 | 개시 | Societe Generale | Sell |
| 2023-05-31 | 개시 | UBS | Buy |
| 2023-04-25 | 개시 | Citigroup | Buy |
| 2023-03-14 | 업그레이드 | Robert W. Baird | Neutral → Outperform |
| 2022-12-07 | 개시 | William Blair | Outperform |
| 2022-10-12 | 개시 | Oppenheimer | Perform |
| 2022-07-29 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2022-06-28 | 재개 | Stifel | Buy |
| 2022-05-03 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2021-12-08 | 개시 | Wells Fargo | Overweight |
| 2021-11-29 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2021-10-29 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2021-10-28 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2021-10-07 | 개시 | Jefferies | Buy |
| 2021-09-23 | 업그레이드 | Redburn | Neutral → Buy |
| 2021-09-07 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2021-07-23 | 개시 | Deutsche Bank | Hold |
| 2021-07-19 | 재개 | Wolfe Research | Outperform |
| 2021-06-18 | 개시 | UBS | Buy |
| 2021-06-04 | 재개 | Robert W. Baird | Outperform |
| 2021-05-10 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2021-04-23 | 개시 | Redburn | Neutral |
| 2021-03-05 | 재확인 | H.C. Wainwright | Neutral |
| 2021-02-02 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2021-01-04 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2020-08-25 | 개시 | Raymond James | Outperform |
| 2020-08-19 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2020-07-29 | 개시 | H.C. Wainwright | Neutral |
| 2020-02-10 | 개시 | BofA/Merrill | Buy |
| 2019-11-05 | 개시 | Credit Suisse | Neutral |
| 2019-10-31 | 업그레이드 | William Blair | Mkt Perform → Outperform |
| 2019-10-22 | 개시 | JP Morgan | Overweight |
| 2019-09-27 | 개시 | Wells Fargo | Market Perform |
| 2019-09-16 | 재개 | Cowen | Outperform |
| 2019-06-28 | 개시 | Robert W. Baird | Outperform |
| 2019-01-18 | 재개 | SunTrust | Buy |
| 2019-01-04 | 개시 | Morgan Stanley | Overweight |
| 2018-12-17 | 개시 | Goldman | Buy |
| 2018-12-14 | 개시 | Wolfe Research | Outperform |
| 2018-06-29 | 개시 | Nomura | Buy |
| 2018-04-09 | 개시 | SunTrust | Buy |
| 2018-01-29 | 재확인 | JMP Securities | Mkt Outperform |
모두보기
알제넥스 NV ADR 주식(ARGX)의 최신 뉴스
Chronic Inflammatory Demyelinating Polyneuropathy Market Report 2025 | Distribution Channel, Route of Administration, and Region Analysis and Forecast to 2035 - GlobeNewswire Inc.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of argenx SE - GlobeNewswire Inc.
argenx ADR Earns Relative Strength Rating Upgrade; Hits Key Benchmark - inkl
Argenx NV ADR stock reaches all-time high at 689.13 USD By Investing.com - Investing.com South Africa
Argenx NV ADR stock reaches all-time high at 689.13 USD - Investing.com Nigeria
argenx ADR earnings beat by $3.26, revenue topped estimates - Investing.com Canada
Weekly Stock Grader Analysis: Upgrades & Downgrades on Top Blue-Chip Stocks - InvestorPlace
Morgan Stanley assumes coverage on argenx stock with Overweight rating - Investing.com
Argenx stock advances as H.C. Wainwright reiterates Buy rating - Investing.com
Argenx stock falls after FDA flags serious risk signal with Vyvgart - Investing.com
argenx SE’s SWOT analysis: biotech stock’s growth potential and challenges - Investing.com
argenx ADR Shows Market Leadership With Jump To 84 RS Rating - Investor's Business Daily
10 Stocks Analysts Are Upgrading Today - Insider Monkey
Argenx Earnings: Vyvgart Delivers Strong Sales Growth; Prefilled Syringe Expands Patient Access - Morningstar
Metric Analysis: Argen X SE ADR (ARGX)’s Key Ratios in the Limelight - DWinneX
Analyzing Ratios: Symbotic Inc (SYM)’s Financial Story Unveiled - DWinneX
Biotech Tumbles. Why Its Sales Beat Wasn't Enough. - Investor's Business Daily
argenx ADR earnings beat by $0.34, revenue topped estimates - Investing.com Nigeria
Crude Oil Gains Over 2%; US Foods Posts Downbeat Earnings - Benzinga
Argenx Stock Extends Rally In A Base As Earnings Loom - Investor's Business Daily
argenx ADR Earns Relative Strength Rating Upgrade - inkl
Argenx stock target holds at $720, H.C. Wainwright affirms Buy rating By Investing.com - Investing.com South Africa
Biotech Leader Surges On 'Best-Case Scenario' For Key Drug - Investor's Business Daily
Guggenheim maintains Buy on Argenx stock, target at $1,100 - Investing.com India
Guggenheim maintains Buy on Argenx stock, target at $1,100 By Investing.com - Investing.com South Africa
Argenx stock target holds at $720, H.C. Wainwright affirms Buy rating - Investing.com India
Stifel maintains $780 target on argenx stock after FDA nod - Investing.com
Stocks To Watch: argenx ADR Sees RS Rating Jump To 91 - Investor's Business Daily
Bernstein double upgrades Argenx to "outperform," raises price target to €755 By Investing.com - Investing.com South Africa
Bernstein double upgrades Argenx to "outperform," raises price target to €755 - Investing.com
Bernstein raises argenx stock rating, hikes target to EUR755 - Investing.com
TD Cowen maintains argenx stock with $761 target, bullish outlook - Investing.com India
TD Cowen maintains argenx stock with $761 target, bullish outlook By Investing.com - Investing.com South Africa
Deutsche Bank lifts argenx stock rating to hold, sets EUR575 target - Investing.com
Deutsche Bank lifts argenx stock rating to hold, sets EUR575 target By Investing.com - Investing.com South Africa
Guggenheim raises argenx stock target to $1,100 on growth outlook - Investing.com India
argenx SE ADR to Host Earnings Call - ACCESS Newswire
Argenx Publishes Long-Term Data At The American Academy Of Neurology 2025 Annual Meeting - Marketscreener.com
Why This Biotech Tumbled For A Second Straight Day - Investor's Business Daily
Argenx Benefits From Multiple Approved Indications of Vyvgart and Strong Uptake - Morningstar
Argenx's Q4 Sales Backed by Vyvgart's Growth, Oppenheimer Says -February 28, 2025 at 11:05 am EST - Marketscreener.com
H.C. Wainwright lifts argenx stock price target to $720 By Investing.com - Investing.com South Africa
H.C. Wainwright lifts argenx stock price target to $720 - Investing.com
Argenx stock target raised to $701 by JMP on VYVGART strength - Investing.com South Africa
알제넥스 NV ADR (ARGX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
6.74%
자본화:
|
볼륨(24시간):